Allergan requests preliminary injunction against Valeant, Pershing Square

Allergan has requested that the U.S. District Court for the Central District of California set an expedited schedule for discovery, as well as a motion for a preliminary injunction against Valeant Pharmaceuticals, Pershing Square Capital Management and its principal, William A. Ackman, for federal securities law violations.As part of the preliminary injunction, Allergan will seek an order prohibiting Valeant, Pershing Square and Ackman from exercising rights and benefits associated with Allergan shares that have been acquired unlawfully, according to a company press release.